Abcam Invests in In Vitro Antibodies

With this purchase, Abcam is adding in vitro recombinant monoclonal antibody technology. Abcam’s RabMAb technology consists of in vivo antibody development/clone selection and in vitro antibody production, according to an Abcam’s CEO Alan Hirzel. Asked about the advantages of in vitro technology, he stated, “It has the ability to produce antibodies to biological targets that do not evoke an immune response or are toxic immunogens.”

London, UK 11/11/15—Life science research tool provider Abcam has agreed to acquire AxioMx for $20 million and an additional $25 million in performance-based payments over five years. Based in Connecticut with 28 employees, AxioMx is a technology-as-a-service company using an in vitro recombinant monoclonal antibody technology, which produces higher quality antibodies faster, according to Abcam. “After an extensive review of alternate scaffold and other in vitro technologies, we are confident that AxioMx has created unique, high quality and economically attractive methods to serve customers in research, diagnostic and drug discovery labs globally,” commented Abcam CEO Alan Hirzel. “We look forward to working with AxioMx to scale up their production and enhance our product offering.” The acquisition is expected to close by the end of November.

< | >